In CAR T cell-treated lymphomas, the T cell rich get richer

Theodora Anagnostou¹, Joshua D Brody^{2

3

4}

Affiliations

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. joshua.brody@mssm.edu.
³ Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. joshua.brody@mssm.edu.
⁴ Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, USA. joshua.brody@mssm.edu.

Comment

Theodora Anagnostou et al. Nat Med. 2022 Sep.

. 2022 Sep;28(9):1757-1758.

doi: 10.1038/s41591-022-01922-z.

Theodora Anagnostou¹, Joshua D Brody^{2

3

4}

¹ Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
² Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. joshua.brody@mssm.edu.
³ Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. joshua.brody@mssm.edu.
⁴ Icahn Genomics Institute, Icahn School of Medicine at Mount Sinai, New York, USA. joshua.brody@mssm.edu.

No abstract available

Comment on

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.
Scholler N, Perbost R, Locke FL, Jain MD, Turcan S, Danan C, Chang EC, Neelapu SS, Miklos DB, Jacobson CA, Lekakis LJ, Lin Y, Ghobadi A, Kim JJ, Chou J, Plaks V, Wang Z, Xue A, Mattie M, Rossi JM, Bot A, Galon J. Scholler N, et al. Nat Med. 2022 Sep;28(9):1872-1882. doi: 10.1038/s41591-022-01916-x. Epub 2022 Aug 29. Nat Med. 2022. PMID: 36038629 Free PMC article.

1. Neelapu, S. S. et al. N. Engl. J. Med. 377, 2531–2544 (2017). - DOI
1. Shalabi, H. et al. Haematologica 103, e215–e218 (2018). - DOI
1. Kline, J., Godfrey, J. & Ansell, S. M. Blood 135, 523–533 (2020). - DOI
1. Bruni, D., Angell, H. K. & Galon, J. Nat. Rev. Cancer 20, 662–680 (2020). - DOI
1. Scholler, N. et al. Nat. Med. https://doi.org/10.1038/s41591-022-01916-x (2022). - DOI - PubMed